Monoclonal antibody · Antagonist of activin A (INHBA) · developed by Regeneron Pharmaceuticals
Garetosmab is a human IgG4 monoclonal antibody that binds activin A and inhibits its signaling, blocking activation of the FOP-mutant ACVR1 receptor. It is studied in fibrodysplasia ossificans progressiva, a condition of heterotopic bone formation.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 14, 2026). Read the full label for the exact wording, limitations and safety information.
Fibrodysplasia Ossificans ProgressivaFOP
Updated Oct 25, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →